Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ExpreS2ion Biotechnologies and the Jenner Institute, University of Oxford Enter a Licensing Agreement

Published: Monday, October 15, 2012
Last Updated: Monday, October 15, 2012
Bookmark and Share
License agreement for the ExpreS2 technology platform.

ExpreS2ion Biotechnologies has announced that they have signed a research license agreement to provide the University of Oxford access to ExpreS2ion's Drosophila Schneider-2 cell-based technology platform - ExpreS2 - for protein production.

The stable, non-lytic protein expression platform, which is fully cGMP compatible, will complement the existing capabilities in protein vaccine expression at the Jenner Institute, University of Oxford.

The platform will be used by various research teams to address expression of complex and "difficult-to-make" proteins.

This license is a perfect example of ExpreS2ion Biotechnologies' vision of making its production platform available to academic centers of excellence globally, in complement to the Company's strategy of making S2 one of the standard protein production platforms in the vaccine and therapeutic protein segments.

Dr. Charlotte Dyring, CEO of ExpreS2ion Biotechnologies, said: "We are delighted that the Jenner Institute at Oxford University has taken a Research License to our proprietary ExpreS2 platform for protein expression. The ExpreS2 platform has shown to provide a way forward to projects with a need for a robust and fully scalable protein production platform, such as certain challenging recombinant subunit vaccine projects.

ExpreS2ion is proud to enter this Agreement with the University of Oxford, one of the world's most prestigious Universities, with well-established, world-recognized medical research."

Dr. Simon Draper, a MRC Research Fellow, commented: "access to the ExpreS2 platform at the Jenner Institute in Oxford will greatly expand our protein vaccine production capabilities. We are looking forward to working with ExpreS2ion Biotechnologies as we develop new clinically-relevant protein vaccines to target difficult pathogens, such as malaria."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

A Vaccine Against Placental Malaria Made with ExpreS2
ExpreS2ion Biotechnologies’ protein expression technology is ready to start human tests in Germany and Benin.
Saturday, March 21, 2015
LMU Munich and ExpreS2ion Biotechnologies Enter a Licensing Agreement
Agreement for use of the ExpreS2 technology platform.
Tuesday, February 24, 2015
Scientific News
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Vaccination Against UTIs
Researchers have successfully vaccinated mice against E.coli growth in the bladder and kidneys.
First Steps to Neutralising Zika
Researchers have discovered a highly potent antibody that neutralises Zika infection at a cellular level.
Human Astrovirus Structure Could Lead to Therapies, Vaccines
Study shows where neutralizing antibody binds to human astrovirus, a leading cause of viral diarrhoea in children, elderly, and the immune-compromised.
Fighting Off HIV Infection Closer to Reality
Researchers have made significant progress in the development of a potential vaccine to protect against HIV infection.
Powerful New Tools to Combat Zika
Researchers have created a way to replicate the stucture of Zika virus, removing the genes that make the virus infectious.
More Immunotherapy Options Approved for Lung Cancer
The FDA has approved a new immunotherapy drug for certain patients with non-small cell lung cancer.
Dissecting Bacterial Infections at the Single-Cell Level
Researchers have used single-cell analysis technology to provide new insight into the Salmonella infection process.
Injectable Biologic Therapy Reduces Triglycerides
Study finds first-of-its-kind therapy promising for patients with high triglycerides, cholesterol.
DNA-Based Zika Vaccine Showed Protection From Infection, Brain Damage and Death
The study is the first of its kind to analyze a vaccine in an animal model that is susceptible to the disease, providing information regarding the protective impact of the immune response in susceptible individuals.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!